Skip to main content

NEWSBRIEF: DeCode Marks Q1 With Strong Revenue Growth, Narrowed Loss

NEW YORK, May 14 - DeCode said last night that an increase in corporate partnerships helped drive strong first-quarter revenue growth and a narrowed net loss.


Total revenue for the period ended March 31 was $9.5 million, an 88-percent increase from the $5.0 million it posted one year ago, the company said.


R&D spending for the quarter dipped to just under $18 million from more than $20 million in the first quarter 2002. This, plus 8.4 million new shares issued following DeCode's acquisition of MediChem Life Sciences in late March, helped narrow net loss to $11.2 million, or $.24 per share, from $16.1 million, or $.37 per share, in the year-ago period.


DeCode said it had slightly more than $147 million in cash and cash equivalents as of March 31.


Click here for more information.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.